Referências
Principais artigos
Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1233-57.Texto completo Resumo
Elliott J, Liu K, Motan T. Guideline no. 444: hirsutism: evaluation and treatment. J Obstet Gynaecol Can. 2023 Dec;45(12):102272. Resumo
Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023 Oct;120(4):767-93.Texto completo Resumo
Artigos de referência
1. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1233-57.Texto completo Resumo
2. Elliott J, Liu K, Motan T. Guideline no. 444: hirsutism: evaluation and treatment. J Obstet Gynaecol Can. 2023 Dec;45(12):102272. Resumo
3. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45.Texto completo Resumo
4. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000 Aug;21(4):363-92.Texto completo Resumo
5. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005 Dec 15;353(24):2578-88. Resumo
6. Messenger AG. The control of hair growth: an overview. J Invest Dermatol. 1993 Jul;101(suppl 1):4S-9S. Resumo
7. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003 May;101(5 Pt 1):995-1007. Resumo
8. DeUgarte CM, Woods KS, Bartolucci AA, et al. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006 Apr;91(4):1345-50.Texto completo Resumo
9. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar-Apr;18(2):146-70. Resumo
10. Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30. Resumo
11. Kirschner MA, Samojlik E, Silber D. A comparison of androgen production and clearance in hirsute and obese women. J Steroid Biochem. 1983 Jul;19(1B):607-14. Resumo
12. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7.Texto completo Resumo
13. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al., eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992:377-81.
14. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023 Oct;120(4):767-93.Texto completo Resumo
15. Hopkinson ZEC, Sattar N, Fleming R, et al. Fortnightly review: polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ. 1998 Aug 1;317(7154):329-32. Resumo
16. Pugeat M, Plotton I, de la Perrière AB, et al. MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis. Eur J Endocrinol. 2018 Apr;178(4):R141-R154.Texto completo Resumo
17. Barth JH, Field HP, Yasmin E, et al. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur J Endocrinol. 2010 Mar;162(3):611-5. Resumo
18. Pugeat M, Déchaud H, Raverot V et al; French Endocrine Society. Recommendations for investigation of hyperandrogenism. Ann Endocrinol (Paris). 2010 Feb;71(1):2-7. Resumo
19. Sathyapalan, T, Atkin SL. Rational testing: Investigating hirsutism. BMJ. 2009 Apr 28;338:b912. Resumo
20. Hahn S, Kuehnel W, Tan S, et al. Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome. Clin Chem Lab Med. 2007;45(2):202-7. Resumo
21. Azziz R, Dewailly D, Owerbach D. Clinical review 56: nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab. 1994 Apr;78(4):810-5. Resumo
22. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003 Jan;169(1):5-11. Resumo
23. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy? J Endocrinol Invest. 2004 Apr;27(4):387-99. Resumo
24. Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789. Obstet Gynecol. 2019 Oct;134(4):e106-e114.Texto completo Resumo
25. Sairish A, Mudasar N, Shayaq ul Abeer R et al. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt. J. Med. Hum.Genet. 2019 Nov 20;20(25).Texto completo
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72.Texto completo Resumo
27. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003 Nov 20;349(21):2035-41. Resumo
28. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004 Feb;89(2):453-62.Texto completo Resumo
29. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000 Jun;21(3):245-91.Texto completo Resumo
30. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-75.Texto completo Resumo
31. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. Resumo
32. Carroll T, Raff H, Findling JW. Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract. 2009 May-Jun;15(4):335-42.Texto completo Resumo
33. Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab. 2009 Oct;94(10):3647-55.Texto completo Resumo
34. Zhang Q, Dou J, Gu W, et al. Reassessing the reliability of the salivary cortisol assay for the diagnosis of Cushing syndrome. J Int Med Res. 2013 Oct;41(5):1387-94.Texto completo Resumo
35. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008 May;93(5):1553-62. Resumo
36. Tuxen MK, Sölétormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995 May;21(3):215-45.
37. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001 Dec;42(12):1795-9.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal